NeuroOne Q3 product rev up 31% to $826K; net loss narrows to $2.8M; oneRF partnership term sheet signed

NEUROONE MEDICAL TECHNOLOGIES Corp

2024-Q3 EPS reported -$0.35 revenue$3,180,719

Product revenue $826K in Q3 FY2024 vs $630K in Q3 FY2023 (+31%); net loss $2.8M vs $3.5M.
Cash and equivalents $1.6M at June 30, 2024; subsequent $2.65M private placement and $3M credit facility in Aug 2024.
Non-binding term sheet with undisclosed global medtech company to distribute OneRF Ablation System.
First OneRF ablation cases completed; CMS granted new ICD-10-PCS code effective Oct 1, 2024.
Operating expenses reduced to $3.1M from $3.8M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.